JP2015501291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501291A5 JP2015501291A5 JP2014532118A JP2014532118A JP2015501291A5 JP 2015501291 A5 JP2015501291 A5 JP 2015501291A5 JP 2014532118 A JP2014532118 A JP 2014532118A JP 2014532118 A JP2014532118 A JP 2014532118A JP 2015501291 A5 JP2015501291 A5 JP 2015501291A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- antibody
- fusion protein
- protein according
- regions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161539416P | 2011-09-26 | 2011-09-26 | |
| US61/539,416 | 2011-09-26 | ||
| PCT/US2012/057393 WO2013049254A1 (en) | 2011-09-26 | 2012-09-26 | Hybrid constant regions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501291A JP2015501291A (ja) | 2015-01-15 |
| JP2015501291A5 true JP2015501291A5 (OSRAM) | 2015-11-19 |
| JP6205363B2 JP6205363B2 (ja) | 2017-09-27 |
Family
ID=47996377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532118A Active JP6205363B2 (ja) | 2011-09-26 | 2012-09-26 | ハイブリッド定常領域 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8952134B2 (OSRAM) |
| EP (1) | EP2760891B1 (OSRAM) |
| JP (1) | JP6205363B2 (OSRAM) |
| CN (1) | CN103974977A (OSRAM) |
| CA (1) | CA2849765C (OSRAM) |
| WO (1) | WO2013049254A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013049254A1 (en) | 2011-09-26 | 2013-04-04 | Jn Biosciences Llc | Hybrid constant regions |
| US9382319B2 (en) | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
| CA2872908C (en) | 2012-05-10 | 2023-11-14 | Gerhard Frey | Multi-specific monoclonal antibodies |
| WO2014022592A1 (en) * | 2012-08-02 | 2014-02-06 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
| US20150038682A1 (en) * | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| AU2014332458B2 (en) * | 2013-09-05 | 2020-03-12 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies |
| TW201619188A (zh) | 2014-03-05 | 2016-06-01 | 優稀美生物醫藥公司 | 多聚體Ｆｃ蛋白質 |
| WO2015132365A1 (en) * | 2014-03-05 | 2015-09-11 | Ucb Biopharma Sprl | Multimeric fc proteins |
| WO2015167948A1 (en) * | 2014-04-30 | 2015-11-05 | Albert Einstein College Of Medicine Of Yeshiva University | Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| DK3247728T3 (da) * | 2015-01-20 | 2020-07-13 | Igm Biosciences Inc | Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf |
| US10604559B2 (en) * | 2015-03-25 | 2020-03-31 | Igm Biosciences, Inc. | Multi-valent hepatitis B virus antigen binding molecules and uses thereof |
| EP3280736A1 (en) * | 2015-04-07 | 2018-02-14 | F. Hoffmann-La Roche AG | Antigen binding complex having agonistic activity and methods of use |
| CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| GB201515745D0 (en) * | 2015-09-04 | 2015-10-21 | Ucb Biopharma Sprl | Proteins |
| CA3012037A1 (en) * | 2016-01-27 | 2017-08-03 | Csl Behring Recombinant Facility Ag | Recombinant igg fc multimers |
| WO2018017889A1 (en) * | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| EP3607091A4 (en) * | 2017-04-07 | 2021-01-20 | IGM Biosciences, Inc. | MODIFIED HUMAN CONSTANT IGM REGIONS FOR THE MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION |
| CN118562001A (zh) | 2017-05-08 | 2024-08-30 | 阿迪马布有限责任公司 | 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法 |
| AU2019224136A1 (en) * | 2018-02-26 | 2020-09-10 | Igm Biosciences, Inc. | Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| WO2019241216A1 (en) | 2018-06-14 | 2019-12-19 | Bioatla, Llc | Multi-specific antibody constructs |
| EP3806903B1 (en) * | 2018-06-14 | 2024-02-14 | 2seventy bio, Inc. | Cd79a chimeric antigen receptors |
| SG11202103720XA (en) * | 2018-10-23 | 2021-05-28 | Igm Biosciences Inc | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES |
| US12492231B2 (en) | 2018-11-14 | 2025-12-09 | Jn Biosciences Llc | Multimeric hybrid Fc proteins for replacement of IVIG |
| BR112021025259A2 (pt) * | 2019-06-14 | 2022-03-15 | 2Seventy Bio Inc | Composições e métodos para tratar câncer |
| CA3173064A1 (en) * | 2020-02-27 | 2021-09-02 | Huahui Health Ltd. | Soluble ace2 and fusion protein, and applications thereof |
| WO2022080912A1 (ko) * | 2020-10-16 | 2022-04-21 | 주식회사 아이엠바이오로직스 | IgM 영역을 이용한 융합단백질 플랫폼 |
| WO2022262321A1 (zh) * | 2021-06-17 | 2022-12-22 | 东莞市朋志生物科技有限公司 | 嵌合的免疫球蛋白 |
| AU2022310862A1 (en) | 2021-07-14 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| AU2023248532A1 (en) | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| WO2024196707A2 (en) * | 2023-03-17 | 2024-09-26 | The Board Of Trustees Of The University Of Illinois | Chimeric antibody molecules based on tetrameric teleost immunoglobulin m |
| WO2025145264A1 (zh) * | 2024-01-02 | 2025-07-10 | 江苏集萃药康生物科技股份有限公司 | 产生人源化抗体的动物模型及其构建方法 |
| KR20250173023A (ko) * | 2024-05-30 | 2025-12-10 | 주식회사 아이엠바이오로직스 | J 사슬에 연결되는 링커 및 이를 포함하는 j 사슬 복합체 |
| CN119638846B (zh) * | 2025-01-09 | 2025-11-04 | 康复大学青岛中心医院 | uMtCK抗体或其抗原结合片段 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8719963D0 (en) * | 1987-08-24 | 1987-09-30 | Cattaneo A | Recombinant dna products |
| DE10001372A1 (de) * | 2000-01-14 | 2001-08-02 | Deutsches Krebsforsch | Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen |
| DE60139864D1 (de) * | 2000-04-28 | 2009-10-22 | Planet Biotechnology Inc | Immunoadhesin zur impfung gegen rhinovirus |
| EP2316951A1 (en) * | 2001-01-17 | 2011-05-04 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| RU2003129528A (ru) * | 2001-03-07 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела |
| WO2005047602A1 (en) * | 2003-11-13 | 2005-05-26 | Dsm Ip Assets B.V. | Use of a vulcanised thermoplastic elastomer or styrene-ethylene-butadiene-styrene polymer as infill material in artificial turf systems |
| EP2162471A1 (en) | 2007-06-08 | 2010-03-17 | Université de la Méditerranée | Compositions and methods for treating pancreatic tumors |
| WO2013049254A1 (en) | 2011-09-26 | 2013-04-04 | Jn Biosciences Llc | Hybrid constant regions |
-
2012
- 2012-09-26 WO PCT/US2012/057393 patent/WO2013049254A1/en not_active Ceased
- 2012-09-26 US US13/627,929 patent/US8952134B2/en active Active
- 2012-09-26 JP JP2014532118A patent/JP6205363B2/ja active Active
- 2012-09-26 EP EP12836751.3A patent/EP2760891B1/en active Active
- 2012-09-26 CA CA2849765A patent/CA2849765C/en active Active
- 2012-09-26 CN CN201280047037.9A patent/CN103974977A/zh active Pending
-
2014
- 2014-11-17 US US14/543,845 patent/US20150073130A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501291A5 (OSRAM) | ||
| JP2015524821A5 (OSRAM) | ||
| SI2699264T1 (en) | Antibodies and other molecules that bind b7-h1 and pd-1 | |
| CA2929256C (en) | Production of t cell retargeting hetero-dimeric immunoglobulins | |
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| JP2023528036A (ja) | Ｔｉｇｉｔに対する抗体 | |
| HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| JP2019513817A (ja) | Ｔｉｇｉｔに対する抗体 | |
| HRP20240415T1 (hr) | Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba | |
| JP2019536470A5 (OSRAM) | ||
| CN109862910A (zh) | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 | |
| JP2019524693A5 (OSRAM) | ||
| JP2021516952A (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| HRP20180937T1 (hr) | Poboljšavanje transporta terapijskih molekula kroz krvno-moždanu barijeru | |
| JP2018525999A5 (OSRAM) | ||
| JP2019513725A5 (OSRAM) | ||
| KR20180095086A (ko) | 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체 | |
| JP2016507523A5 (OSRAM) | ||
| JP2016507555A5 (OSRAM) | ||
| CA2896548A1 (en) | Multivalent binding protein compositions | |
| Taylor et al. | Nanocell targeting using engineered bispecific antibodies | |
| JP2016531100A5 (OSRAM) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene |